Sensitivity of a novel model of mammary cancer stem cell-like cells to TNF-related death pathways

Cancer Immunology, Immunotherapy

Volumn 61, Issue 8, 2012, Pages 1255-1268

  Li, Ming ^a   Knight, Deborah A ^a   Smyth, Mark J ^a   Stewart, Trina J ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Breast cancer; Cancer stem cells; Fas; Immunotherapy; TNF related cell death; TRAIL

Indexed keywords

CD155 ANTIGEN; CD24 ANTIGEN; CELL PROTEIN; DEATH RECEPTOR 5; FAS ANTIGEN; FAS LIGAND; HERMES ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE ANTIGEN; PROTEIN RAE 1; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER STEM CELL; CELL PROLIFERATION; CELL SUBPOPULATION; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; MOUSE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD24; ANTIGENS, CD44; ANTIGENS, CD95; CELL DEATH; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; IMMUNOPHENOTYPING; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASTIC STEM CELLS; RADIATION TOLERANCE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84865758923     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1200-1     Document Type: Article

References (34)

1. Cobaleda C, Cruz JJ, Gonzalez-Sarmiento R, Sanchez-Garcia I, Perez-Losada J (2008) The emerging picture of human breast cancer as a stem cell-based disease. Stem Cell Rev 4:67-79. doi: 10.1007/s12015-008-9012-6
2. Dontu G, Liu S, Wicha MS (2005) Stem cells in mammary development and carcinogenesis: implications for prevention and treatment. Stem Cell Rev 1:207-213. doi:10.1385/SCR:1:3:207 (Pubitemid 41737097)
3. Baumann M, Krause M, Hill R (2008) Exploring the role of cancer stem cells in radioresistance. Nature Rev Cancer 8:545-554. doi:10.1038/nrc2419 (Pubitemid 351881850)
4. Eyler CE, Rich JN (2008) Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol Off J Am Soc Clin Oncol 26:2839-2845. doi:10.1200/JCO.2007.15.1829
5. Li X, Lewis MT, Huang J et al (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100:672-679. doi:10.1093/jnci/djn123
6. Woodward WA, Bristow RG (2009) Radiosensitivity of cancerinitiating cells and normal stem cells (or what the Heisenberg uncertainly principle has to do with biology). Semin Radiat Oncol 19:87-95. doi:10.1016/j.semradonc.2008.11.003
7. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983-3988. doi:10.1073/ pnas.0530291100 (Pubitemid 36418143)
8. Oliveira LR, Jeffrey SS, Ribeiro-Silva A (2010) Stem cells in human breast cancer. Histol Histopathol 25:371-385
9. Schmidt C (2008) Lapatinib study supports cancer stem cell hypothesis, encourages industry research. J Natl Cancer Inst 100:694-695. doi:10.1093/jnci/djn168
10. Shipitsin M, Polyak K (2008) The cancer stem cell hypothesis: in search of definitions, markers, and relevance. Lab Invest 88:459-463. doi:10.1038/labinvest.2008.14 (Pubitemid 351581449)
11. Ginestier C, Hur MH, Charafe-Jauffret E et al (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:555-567. doi:10.1016/j.stem.2007.08.014 (Pubitemid 350056407)
12. Zitvogel L, Kepp O, Kroemer G (2011) Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 8:151-160. doi:10.1038/nrclinonc.2010.223
13. Locher C, Conforti R, Aymeric L et al (2010) Desirable cell death during anticancer chemotherapy. Ann N Y Acad Sci 1209:99- 108. doi:10.1111/j.1749-6632. 2010.05763.x
14. Stewart TJ, Greeneltch KM, Reid JE, Liewehr DJ, Steinberg SM, Liu K, Abrams SI (2009) Interferon regulatory factor-8 modulates the development of tumour-induced CD11b?Gr-1 myeloid cells. J Cell Mol Med 13:3939-3950. doi:10.1111/j.1582-4934. 2009.00685.x
15. Stewart TJ, Abrams SI (2007) Altered immune function during long-Term host-Tumor interactions can be modulated to retard autochthonous neoplastic growth. J Immunol 179:2851-2859
16. Nakayama M, Harada N, Okumura K, Yagita H (2003) Characterization of murine TWEAK and its receptor (Fn14) by monoclonal antibodies. Biochem Biophys Res Commun 306:819-825 (Pubitemid 36776204)
17. Latour S, Fridman WH, Daeron M (1996) Identification, molecular cloning, biologic properties, and tissue distribution of a novel isoform of murine low-Affinity IgG receptor homologous to human Fc gamma RIIB1. J Immunol 157:189-197 (Pubitemid 26190547)
18. Stewart TJ, Drane D, Malliaros J, Elmer H, Malcolm KM, Cox JC, Edwards SJ, Frazer IH, Fernando GJ (2004) ISCOMATRIX adjuvant: An adjuvant suitable for use in anticancer vaccines. Vaccine 22:3738-3743. doi:10.1016/j.vaccine.2004.03. 026 (Pubitemid 39099650)
19. Chan CJ, Andrews DM, McLaughlin NM, Yagita H, Gilfillan S, Colonna M, Smyth MJ (2010) DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases. J Immunol 184:902-911. doi:10.4049/jimmunol.0903225
20. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, Wicha MS (2003) In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17:1253-1270. doi:10.1101/gad.1061803 (Pubitemid 36583168)
21. Takeda K, Yamaguchi N, Akiba H et al (2004) Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med 199:437-448. doi:10.1084/jem.20031457 (Pubitemid 38233828)
22. Keysar SB, Jimeno A (2010) More than markers: biological significance of cancer stem cell-defining molecules. Mol Cancer Ther 9:2450-2457. doi:10.1158/1535-7163.MCT-10-0530
23. Sneddon JB, Werb Z (2007) Location, location, location: the cancer stem cell niche. Cell Stem Cell 1:607-611. doi:10.1016/ j.stem.2007.11.009 (Pubitemid 350215340)
24. Borovski T, De Sousa EMF, Vermeulen L, Medema JP (2011) Cancer stem cell niche: the place to be. Cancer Res 71:634-639. doi:10.1158/0008-5472.CAN-10-3220
25. Hurt EM, Farrar WL (2010) Purification and characterization of cancer stem cells. In: Farrar WL (ed) Cancer stem cells, 1st edn. Cambridge University Press, New York, NY, pp 1-14
26. Nakshatri H, Srour EF, Badve S (2009) Breast cancer stem cells and intrinsic subtypes: controversies rage on. Curr Stem Cell Res Ther 4:50-60
27. Mahalingam D, Szegezdi E, Keane M, de Jong S, Samali A (2009) TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treat Rev 35:280-288. doi:10.1016/j.ctrv. 2008.11.006
28. Ginestier C, Liu S, Diebel ME et al (2010) CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Investig 120:485-497. doi:10.1172/JCI39397
29. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S (1993) Lethal effect of the anti-Fas antibody in mice. Nature 364:806-809. doi: 10.1038/364806a0 (Pubitemid 23261761)
30. Cretney E, Takeda K, Smyth MJ (2007) Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway. Int J Biochem Cell Biol 39:280-286. doi:10.1016/j.biocel.2006.10.005 (Pubitemid 44855666)
31. Wu GS (2009) TRAIL as a target in anti-cancer therapy. Cancer Lett 285:1-5. doi:10.1016/j.canlet.2009.02.029
32. Abdulghani J, El-Deiry WS (2010) TRAIL receptor signaling and therapeutics. Expert Opin Ther Targets 14:1091-1108. doi: 10.1517/14728222.2010. 519701
33. Rajeshkumar NV, Rasheed ZA, Garcia-Garcia E, Lopez-Rios F, Fujiwara K, Matsui WH, Hidalgo M (2010) A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-Term disease control in human pancreatic cancer model. Mol Cancer Ther 9:2582-2592. doi:10.1158/1535-7163.MCT-10-0370
34. Deonarain MP, Kousparou CA, Epenetos AA (2009) Antibodies targeting cancer stem cells: A new paradigm in immunotherapy? MAbs 1:12-25